Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06436222

Effectiveness of HVNI in Preterm Infants With Moderate Respiratory Distress

Effectiveness of High Velocity Nasal Insufflation (HVNI) in Infants <32 Weeks Gestational Age(GA) or Birth Weight <1500 Grams With Moderate Respiratory Distress in Dr.Cipto Mangunkusumo Hospital

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
60 (estimated)
Sponsor
Indonesia University · Academic / Other
Sex
All
Age
28 Weeks – 32 Weeks
Healthy volunteers
Accepted

Summary

Neonatal respiratory distress is a common problem in preterm infants. The application of CPAP is widely used in neonatal units as a primary mode of respiratory support for respiratory distress. However, discomfort, nasal injuries, and fixation difficulties have been reported as obstacles when applying CPAP. High velocity nasal insufflation (HVNI) may serve as an alternative to CPAP. Trials are needed to evaluate the effectiveness of HVNI in reducing the incidence of respiratory distress. The aim of this study is to compare the clinical effectiveness and safety of HVNI as an alternative therapy to CPAP in premature infants with moderate respiratory distress. This study is a prospective, non-inferiority, randomized, unblinded controlled trial to compare the efficacy of HVNI and CPAP. The subjects were randomly allocated to receive either HVNI or CPAP according to the study protocol. They were randomly assigned using blocks of four. The completion of HVNI therapy was determined by therapeutic failure within 72 hours following enrollment, indicated by the need for intubation.

Conditions

Interventions

TypeNameDescription
DEVICEHVNIPreterm infants with gestational age (GA) less than 32 weeks or birth weight less than 1500 grams. The infant has moderate respiratory distress (Downe score ≤ 6) detected within 24 hours after birth.

Timeline

Start date
2024-05-20
Primary completion
2024-12-31
Completion
2024-12-31
First posted
2024-05-31
Last updated
2024-05-31

Regulatory

Source: ClinicalTrials.gov record NCT06436222. Inclusion in this directory is not an endorsement.